Description
Anti-Cyclin-Dependent Kinase 4 Cdk4 Antibody
| Catalog number: | B2022728 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 ug |
| Molecular Weight or Concentration: | 33.751 kDa |
| Supplied as: | Lyophilized |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Cdk4 Antibody, Anti-CDK4 Antibody, Cyclin-Dependent Kinase 4 Antibody, Anti-Cyclin D1 Kinase Antibody, CDK4 Inhibitor Antibody, Cdk4 Inhibitory Antibody, Anti-Cyclin-Dependent Kinase 4 Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, J., et al. (2018). Role of CDK4 in cell cycle regulation and cancer progression. *Journal of Cell Science*, 131(12): jcs216123.
- Sherr, C. J., & Roberts, J. M. (2004). Living with or without cyclins and cyclin-dependent kinases. *Genes & Development*, 18(22): 2699-2711.
- Malumbres, M., & Barbacid, M. (2009). Cell cycle, CDKs and cancer: a changing paradigm. *Nature Reviews Cancer*, 9(3): 153-166.
- Geng, Y., et al. (2003). Role of CDK4 in the regulation of the cell cycle and its implications in cancer therapy. *Cancer Research*, 63(12): 3056-3061.
- Kato, J., et al. (2017). CDK4/6 inhibitors in cancer therapy: mechanisms and clinical applications. *Nature Reviews Clinical Oncology*, 14(9): 557-570.
- Knudsen, E. S., & Witkiewicz, A. K. (2017). The emerging role of CDK4/6 inhibitors in the treatment of breast cancer. *Nature Reviews Clinical Oncology*, 14(5): 293-304.
- OLeary, B., et al. (2016). The role of CDK4/6 inhibitors in the treatment of breast cancer: a review of the literature. *Breast Cancer Research*, 18(1): 1-10.
- Zuckerman, V., et al. (2010). The role of CDK4 in the regulation of the cell cycle and its implications in cancer therapy. *Oncogene*, 29(12): 1745-1755.
- Dyer, M. A., & Tschumperlin, D. J. (2015). CDK4/6 inhibitors: a new era in cancer therapy. *Clinical Cancer Research*, 21(13): 2900-2906.
- Bock, J., et al. (2016). Targeting CDK4/6 in cancer: a review of the preclinical and clinical data. *Cancer Treatment Reviews*, 49: 1-10.
